Completed PHASE3 INTERVENTIONAL NCT00246207

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

An Open-label Study Evaluating the Safety and Effectiveness of OROS Methylphenidate Hydrochloride (CONCERTA) in Adults With Attention Deficit Hyperactivity Disorder

Sponsor: Janssen-Ortho Inc., Canada

Conditions Attention Deficit Disorder With Hyperactivity

Interventions CONCERTA (OROS methylphenidate hydrochloride)

Updated 5 times since 2017 Last updated: Feb 9, 2012 Started: Mar 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Attention Deficit Disorder With Hyperactivity and is currently completed. Janssen-Ortho Inc., Canada leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Ortho Inc., Canada

Data source: Janssen-Ortho Inc., Canada

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.